08:00 EST Arrowhead (ARWR) files automatic mixed securities shelf
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARWR:
- Arrowhead price target raised to $80 from $52 at RBC Capital
- Analyst Recommends Buy Rating for Arrowhead Pharmaceuticals Due to Promising Obesity Treatment Potential
- Arrowhead price target raised to $81 from $62 at BofA
- Cautious Optimism for Arrowhead Pharmaceuticals Amid Competitor’s Positive Obesity Treatment Data
- Morgan Stanley sees positive readthrough to Arrowhead pipeline from Wave data